SCHEMBL22557714

SCHEMBL22557714

CC(=O)N1CCC(CSc2ccc(Br)c(C(N)=O)c2)CC1

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PARP1 P09874 2/20 0.38
F10 P00742 2/20 0.36
RAB9A P51151 1/20 0.36
JAK2 O60674 2/20 0.36
JAK3 P52333 2/20 0.36
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
THRB P10828 1/20 0.35
QDPR P09417 1/20 0.35
SYK P43405 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30978716 1.00 IRAK4 (0.39) IRAK4SMN1; SMN2PARP1F10RAB9A
SCHEMBL22557746 0.84 DPP4 (0.39) RAB9ATHRBQDPR
SCHEMBL30978719 0.84 DPP4 (0.39) RAB9ATHRBQDPR
SCHEMBL22557666 0.82 AR (0.45) RAB9AALDH1A1QDPR
SCHEMBL22557673 0.81 ALDH1A1 (0.48) SMN1; SMN2RAB9AALDH1A1PKMTHRB
SCHEMBL22585308 0.81 RAB9A (0.34) SMN1; SMN2RAB9AALDH1A1THRBQDPR
SCHEMBL31245781 0.79 SMN1; SMN2 (0.36) SMN1; SMN2PARP1RAB9AJAK2ALDH1A1
SCHEMBL21742986 0.79 SMN1; SMN2 (0.36) SMN1; SMN2PARP1RAB9AJAK2ALDH1A1
SCHEMBL22585179 0.72 HDAC3 (0.44) SMN1; SMN2RAB9AALDH1A1
SCHEMBL22585253 0.71 HDAC3 (0.44) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162836-B2 N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use Modern Biosciences Limited (GB) 2024-12-10 US disclosed
CN-113766953-B N-acyl- {4- [ (4-aryl-phenyl) sulfonylmethyl ] piperidine } compounds and their therapeutic uses 现代生物科学有限公司 2024-07-02 CN disclosed
US-20230022917-A1 N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE ISTESSO THERAPEUTICS LIMITED (GB) 2023-01-26 US disclosed
EP-3956030-A1 N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE Modern Biosciences Limited (GB) 2022-02-23 EP disclosed
CN-113766953-A N-acyl- {4- [ (4-aryl-phenyl) sulfonylmethyl ] piperidine } compounds and their therapeutic use 现代生物科学有限公司 2021-12-07 CN disclosed
WO-2020212581-A1 N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE Modern Biosciences Limited (GB) 2020-10-22 WO disclosed
WO-2020212581-A1 N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE Modern Biosciences Limited (GB) 2020-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162836-B2 N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use MCL1, BCL9, BCL9L IRAK4 317/4885SMN1; SMN2 1565/4885PARP1 76/4885
US-20230022917-A1 N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE MCL1, BCL9, BCL9L IRAK4 317/4885SMN1; SMN2 1565/4885PARP1 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.